A structural and functional imaging research of children with Attention Deficit Hyperactivity Disorder (ADHD)

Structural and functional imaging maps of children with Attention Deficit Hyperactivity Disorder (ADHD) using Magnetic Resonance Imaging (MRI) scan of the brain and methylphenidate (MPH)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000059369

Enrollment

Registered

2008-01-30

Start date

2007-08-21

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

All participants will be scanned by a MRI scanner. The total time of a scan session is about 45 minutes and data of structural and functional images of the subjects’ brains will be collected. In the functional part, the subjects will perform a cognitive task. Children with ADHD will be scanned twice. About 1 hour before one of the scan sessions, the patients will take a single dose (10 mg) of MPH orally, which is a drug commonly used in the treatment of ADHD. Then the patients will be scanned. (About 1 hour before the other scan session, the patients will take the placebo, which is described in the “Comparator / control treatment” part of the form.) The order of the two sessions will be counterbalanced across the patients. The interval between the two sessions will be about 1 week, which is thought to be enough for the clearance of the drug.

Study design

Allocation

Non-randomised trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

Male

Age

11 Years to 16 Years

Healthy volunteers

Yes

Inclusion criteria

The patients should met the diagnosis of ADHD, which is based on DSM-IV criteria and have a full scale IQ higher than 80 measured by the Wechsler Intelligence Scale for Chinese Children-Revised (WISCC-R).

Exclusion criteria

1) right-handedness; 2) no lifetime history of head trauma with loss of consciousness; 3) no history of neurological illness or other serious physical diseases; 4) no history of psychiatric disorders including schizophrenia, affective disorders, anxiety, Tourette disorder, pervasive developmental disorder and mental retardation.

Outcome results